Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Compound Biejia Ruangan Tablets in Hepatocellular Carcinoma: NCT07481032 Clinical Landscape Report 2026
15 October 2026
NCT07481032 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DC cells(Shanghai Cell Therapy Group) in Solid tumor: NCT07479667 Clinical Landscape Report 2026
15 October 2026
NCT07479667 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Pancreatic carcinoma non-resectable: NCT07481383 Clinical Landscape Report 2026
15 October 2026
NCT07481383 clinical landscape for Pancreatic carcinoma non-resectable: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
DA-3501 in Pancreatic Ductal Adenocarcinoma: NCT07481357 Clinical Landscape Report 2026
15 October 2026
NCT07481357 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
EB-DNK101 in Advanced Pancreatic Ductal Adenocarcinoma: NCT07480928 Clinical Landscape Report 2026
15 October 2026
NCT07480928 clinical landscape for Advanced Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
MRG-006A in Advanced Hepatocellular Carcinoma: NCT07479485 Clinical Landscape Report 2026
15 October 2026
NCT07479485 clinical landscape for Advanced Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Tislelizumab in Unresectable Hepatocellular Carcinoma: NCT07480382 Clinical Landscape Report 2026
15 October 2026
NCT07480382 clinical landscape for Unresectable Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Crisugabalin in Young onset Parkinson disease: NCT07483398 Clinical Landscape Report 2026
15 October 2026
NCT07483398 clinical landscape for Young onset Parkinson disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ML-261(Moonlight Bio) in Small Cell Lung Cancer: NCT07488923 Clinical Landscape Report 2026
15 October 2026
NCT07488923 clinical landscape for Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Unresectable Hepatocellular Carcinoma: NCT07482059 Clinical Landscape Report 2026
15 October 2026
NCT07482059 clinical landscape for Unresectable Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Nogapendekin alfa inbakicept-pmln in Pancreatic Ductal Adenocarcinoma: NCT07488884 Clinical Landscape Report 2026
15 October 2026
NCT07488884 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
TL-003 in Colitis, Ulcerative: ACTRN12626000354381 Clinical Landscape Report 2026
15 October 2026
ACTRN12626000354381 clinical landscape for Colitis, Ulcerative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.